Fluorescent IGF-II analogues for FRET-based investigations into the binding of IGF-II to the IGF-1R†

J. M. Cottam Jones, a P. W. R. Harris, b,c,d D. B. Scanlon, a B. E. Forbes, e,f M. A. Brimble c,d and A. D. Abell a,g

The interaction of IGF-II with the insulin receptor (IR) and type 1 insulin-like growth factor receptor (IGF-1R) has recently been identified as potential therapeutic target for the treatment of cancer. Understanding the interactions of IGF-II with these receptors is required for the development of potential anticancer therapeutics. This work describes an efficient convergent synthesis of native IGF-II and two non-native IGF-II analogues with coumarin fluorescent probes at residues 19 and 28. These fluorescent analogues bind with nanomolar affinities to the IGF-1R and are suitable for use in fluorescence resonance energy transfer (FRET) studies. From these studies the F19Cou IGF-II and F28Cou IGF-II proteins were identified as good probes for investigating the binding interactions of IGF-II with the IGF-1R and its other high affinity binding partners.

Introduction

Insulin-like growth factor II (IGF-II) is a 67-residue regulatory peptide that binds with high affinity to three receptors; the insulin receptor (IR), type 1 insulin-like growth factor receptor (IGF-1R), and type 2 insulin-like growth factor receptor (IGF-2R). The binding of IGF-II to these receptors promotes a range of responses, including cell growth, proliferation, differentiation and apoptosis.1-6

Deregulation of the IGF system results in elevated levels of circulating IGF-II with an associated increase in binding to the IGF-1R and IR-A (insulin receptor isoform A).6-15 Activation of both receptors can then promote cancer cell growth and metastasis.16,17 While a structure of insulin bound to a fragment of the IR has been reported,18,19 detailed structural information on the interaction of IGF-II with either the IR-A or IGF-1R remains elusive.

A comparison of IGF-II and IGF-II analogues with the related ligands, IGF-I and insulin in competition binding assays on soluble receptors or cells expressing either the IR-A or the IGF-1R, does however, provide some information on the mechanisms of interaction of IGF-II with IGF-1R and IR-A.19-32 Alanine mutagenesis of IGF-II has identified two separate binding sites (defined as sites 1 and 2) that are critical for binding to the IGF-1R and IR and are analogous to the two insulin binding sites that bind the IR.33 However, precise molecular details of the contact residues within the receptors remain ill-defined. X-ray crystallographic analysis of insulin bound to a fragment of the IR16,19 suggests that the site 1 residues of IGF-II most likely contact the leucine-rich domain 1 and α-CT peptide.

Here we present the convergent synthesis of F19Cou IGF-II and F28Cou IGF-II and their use in a fluorescence resonance energy transfer (FRET) based study to define the interactions of IGF-II with the IGF-1R. A coumaryl glycine acceptor (see Scheme 1) was incorporated into IGF-II at Phe28 and at Phe19 to probe interactions with sites 1 and 2, respectively. The coumaryl glycine probe has advantages of a strong quantum yield and a large Stokes shift, while also exhibiting appropriate spectral overlap with tryptophan (Trp) as a FRET donor.34-41 Trp was deemed a suitable donor as these residues were identified...
as being positioned nearby likely IGF-II binding sites through analysis of the X-ray crystal structure of the Insulin:IR complex as well as IR and IGF-1R mutagenesis data.48-50

There are three reports on the chemical synthesis of IGF-II and all utilise a similar linear approach that requires multi-step post-cleavage deprotections and lengthy multi-step purification protocols.44-47 Furthermore, none are suitable for the incorporation of unnatural amino acids. The yield of IGF-II is presented in only two of these syntheses and this is somewhat problematically reported to be of the order of 2% (based on the starting resin). Thus a more modular approach to the coumaryl glycine-containing IGF-II analogues was deemed necessary. With this in mind we have developed an efficient convergent synthesis of IGF-II and its application to the preparation of two specific fluorescent IGF-II analogues; F19Cou IGF-II and F28Cou IGF-II (see Scheme 1).

Results and discussion

The six Cys residues (Cys9, Cys21, Cys46, Cys47, Cys51 and Cys60) of the IGF-II provide suitable sites for a native chemical ligation (NCL) approach to the synthesis.48 The viability of such an approach to IGF-II and its analogues was first investigated with a two fragment-based synthesis of native IGF-II. This began with the synthesis of a C-terminal IGF-II (47–67) fragment by standard Fmoc-SPPS and the N-terminal IGF-II (1–20) thioester using an in situ neutralisation Boc-SPPS protocol (see ESIF).49 Ligation of the N-terminal IGF-II (1–20) and IGF-II (Thz-46) thioester with the C-terminal IGF-II (47–67) fragment, in the presence of 6.0 M GnHCl, 200 mM Na2HPO4, 20 mM TCEP, 200 mM MPAA,50 at a pH of 6.8, gave the desired native IGF-II peptide (see ESIF). However, access to sufficient quantities of the required 46-residue fragment, or unnatural amino acid-containing derivatives thereof, proved impractical due to low yields associated with the assembly and purification of such a long peptide sequence. Therefore, a more convergent, three fragment-based approach to synthesis of the native IGF-II and fluorescent IGF-II analogues (F19Cou IGF-II and F28Cou IGF-II) was investigated as summarised in Scheme 1.

The IGF-II peptides were assembled from three fragments of 20, 26 and 21 amino acids in length respectively, using iterative Val20 to Cys31 and Cys46 to Cys47 ligation as depicted in Scheme 1. Specific ligation sites were selected based on the size of the respective fragments and the predicted reactivity of the C-terminal residue bearing the thioester.51 Thus the Val20–Cys21 junction (rather than Leu8–Cys9) was selected as the N-terminal ligation site, where disconnection here gives rise to peptide fragments of similar size (approx. 20 residues) see ESIF† for IGF-II sequence).

The peptide thioesters (IGF-II (1–20) and IGF-II (Thz-46)) were prepared using an in situ neutralisation Boc-SPPS protocol,59 and the C-terminal IGF-II (47–67) fragment was synthesised using standard Fmoc-SPPS (see ESIF). The use of a manual in situ neutralisation Boc-SPPS protocol for the preparation of the N-terminal IGF-II (1–20) thioester prevented the formation of deletion by-products, which resulted from on-resin aggregation using an Fmoc-SPPS approach.57 The use of TFA in the deprotection of the Nα-Boc amino functionality was key in disrupting on-resin aggregation.52,53

The one-pot three fragment synthesis of the native IGF-II peptide (summarised in Fig. 1) began with ligation of the IGF-II (Thz-46) thioester with the C-terminal IGF-II (47–67) fragment under standard NCL conditions.50,54 LCMS analysis of the reaction mixture, after 60 min, revealed complete conversion to the IGF-II (Thz-67) fragment (see Fig. 1b). Treatment of this ligation mixture with methoxamine hydrochloride (0.2 M) at pH 3.55 for 8 h gave complete conversion (as determined by LCMS) of the thiazolidone (Thz) to cysteine (refer to Fig. 1c). The ligation mixture was then returned to pH 6.8 and the N-terminal IGF-II (1–20) thioester was added. Complete conversion to the desired native IGF-II peptide was apparent after 36 h, based on LCMS analysis as shown in Fig. 1d, despite the expected slow reactivity of Val thioester.51 Native IGF-II peptide was isolated by solid phase extraction and purified by RP-HPLC. This material was then folded using the

Scheme 1 One-pot, three fragment ligation approach to the synthesis of IGF-II analogues. Inset: coumaryl glycine acceptor. NCL conditions: 6.0 M GnHCl, 200.0 mM Na2HPO4, 20.0 mM TCEP, 200.0 mM MPAA, pH of 6.7–7.0. Folding conditions: 2.50 M urea, 0.70 M Tris, 12.5 mM glycine, 2.0 mM EDTA, 0.5 mM DTT, 1.25 mM 2-hydroxyethyl disulphide at a pH of 9.1 and protein concentration of <0.10 mg mL−1.
pared to previous reports.44,45

in improved purity (>98% based on RP-HPLC, see Fig. 2b) com-

valine-based ligation between the N-terminal IGF-II (1–20) thioester and C-terminal IGF-II (47–67) fragment after 36 h.

thioester and C-terminal IGF-II (47–67) fragment. Folding of

optimised folding conditions described by Delaine et al.56 (see ESIf) to give synthetic native IGF-II in an overall yield of 0.3% (from the IGF-II (Thz-67) thioester fragment) and importantly in improved purity (>98% based on RP-HPLC, see Fig. 2b) compared to previous reports.44,45

The methodology was next applied to the synthesis of the two fluorescent IGF-II analogues, F19Cou IGF-II and F28Cou IGF-II. The F19Cou IGF-II peptide was synthesised by ligation of the N-terminal F19Cou IGF-II (1–20) thioester, IGF-II (Thz-46) thioester and C-terminal IGF-II (47–67) fragment. The F28Cou IGF-II peptide was similarly synthesised by ligation of the N-terminal IGF-II (1–20) thioester, F28Cou IGF-II (Thz-46) thioester and C-terminal IGF-II (47–67) fragment. Folding of the fluorescent IGF-II peptides was essentially as described above for the native IGF-II protein, and resulted in a single folded product (see ESIf).56 RP-HPLC was used to confirm the correct folding of the synthetic IGF-II analogues, which was consistent with folding profiles observed for other IGF-II analogues.33,57 Both the F19Cou IGF-II and F28Cou IGF-II proteins were isolated in excellent purity (>98% based on RP-HPLC, see Fig. 2c and d), and in moderate to low overall yields of 1% (from the IGF-II (Thz-67) thioester fragment) and 0.1% (from the F28Cou IGF-II (Thz-67) thioester fragment) respectively.

A real advantage of the ligation methodology is that it is robust and highly reproducible. Sufficient quantities of peptide were obtained for the study, however the yield from protein folding could likely be improved if conducted on a larger scale.

Competition binding assays of the synthetic IGF-II analogues with the IGF-1R were conducted using solubilized immunocaptured IGF-1R58 and the resulting binding curves are depicted in Fig. 3. The IC50 values for the binding of the synthetic native IGF-II (two fragment synthesis) and synthetic native IGF-II (three fragment synthesis), to the IGF-1R were determined to be 2.1 ± 1.6 nM and 2.0 ± 1.2 nM respectively, see Table 1. These values are essentially identical to the IC50 values determined and those reported for the recombinant native IGF-II protein (2.1 ± 1.2 nM).56 The F19Cou IGF-II and the F28Cou IGF-II proteins gave IC50 values of 7.0 ± 1.3 nM and 6.5 ± 1.5 nM respectively. A small decrease in affinity compared to the native IGF-II protein was not unexpected since both Phe19 and Phe28 are reported to be important residues for IGF-II binding.33 Importantly, the observed three-fold decrease in binding affinity is consistent with reports for other IGF-II analogues with substitutions at Phe19 and Phe28.33,56

A FRET analysis of the binding of both fluorescent IGF-II analogues to a soluble form of the IGF-1R (sIGF-1R)59 was next investigated. Native tryptophan fluorescence from the IGF-1R

**Fig. 1** LCMS analysis of the one-pot three fragment synthesis of the native IGF-II peptide. Analysis of the cysteine-based ligation between the IGF-II (Thz-46) thioester and C-terminal IGF-II (47–67) fragment after (a) 2 min and (b) 60 min; (c) analysis of the thiazolidone de-protection of the IGF-II (Thz-67) fragment after 8 h; (d) analysis of the valine-based ligation between the N-terminal IGF-II (1–20) thioester and IGF-II (21–67) fragment after 36 h.

**Fig. 2** Purified synthetic IGF-II proteins synthesised using NCL approach. (a) Native IGF-II (2 fragment); (b) native IGF-II (3 fragment); (c) F19Cou IGF-II; (d) F28Cou IGF-II.

**Fig. 3** Competitive binding of the synthetic native IGF-II, F19Cou IGF-II, and F28Cou IGF-II proteins to immunocaptured IGF-1R. Immunocaptured IGF-1R was incubated with europium-labelled IGF-II (EuiGF-II) in the absence or presence of increasing concentrations of recombinant native IGF-II (black, dashed line), synthetic native IGF-II (two fragment: grey squares; three fragment: brown diamonds), F19Cou IGF-II (orange circles) or F28Cou IGF-II (green triangles). Results are expressed as a percentage of binding in the absence of competing ligand (Bo). Graphs show data pooled from three separate experiments and each data point is measured in triplicate per experiment, except data from the native IGF-II protein (two fragment) was derived from a single experiment performed in triplicate. Data is shown as the mean ± S.E. Error bars are shown when greater than the size of the symbols.
Table 1  IC₅₀ values derived from competitive binding assays of the synthetic IGF-II analogues binding to immunocaptured IGF-1R. Where the affinity relative to IGF-II is the IC₅₀ relative to that of IGF-II binding to the IGF-1R (IC₅₀ IGF-II/IC₅₀ IGF-II analogue) and is expressed as a percentage of IGF-II binding. IGF-II ± S.E is derived from at least three separate experiments performed in triplicate.

| Protein                  | IC₅₀ (nM) | Affinity relative to recombinant native |
|--------------------------|-----------|----------------------------------------|
| Recombinant native IGF-II| 2.1 ± 1.2 | 100                                    |
| Native IGF-II (2 fragment)* | 2.1 ± 1.6 | 100                                    |
| Native IGF-II (3 fragment) | 2.0 ± 1.2 | 105                                    |
| F19Cou IGF-II            | 7.0 ± 1.3 | 30                                     |
| F28Cou IGF-II            | 6.5 ± 1.5 | 32                                     |

* Results derived from a single experiment performed in triplicate.

was used as the donor, with the coumarin contained within synthetic F19Cou IGF-II and F28Cou IGF-II proteins acting as an acceptor. Binding was investigated using a sensitized emission approach, where the presence of a FRET signal requires the tryptophan fluorescence of the IGF-1R to be quenched and the coumarin fluorescence of the IGF-II analogue to be sensitized. The experiment involved titration of an IGF-II analogue (acceptor) into a solution of sIGF-1R (donor) until the protein and receptor were present in an equimolar ratio. After each addition of an IGF-II analogue, the sample was excited at 280 nm and 320 nm and the fluorescence emission spectrum for each wavelength was recorded (see ESI†). Control experiments for the IGF-II analogues (acceptor) and sIGF-1R (donor) were also analysed using the same methodology.

The resulting fluorescence emission spectra for the native IGF-II, F19Cou IGF-II, and F28Cou IGF-II, after excitation at 280 nm and 320 nm are shown in Fig. 4–6 respectively. Specifically fluorescence emission spectra of the IGF-II analogues (acceptor) in the absence and presence of the donor (sIGF-1R), the emission of the donor (sIGF-1R) and the summed emission spectrum resulting from the sum of the individual donor (sIGF-1R) and acceptor (F19Cou IGF-II) spectra (blue solid lines) are displayed. Spectra were collected when the protein and receptor were present in an equimolar ratio at concentration of 0.20 µM, in 0.1 M sodium phosphate buffer at pH 7.2 after excitation at 280 nm or 320 nm. Spectra are derived from a single experiment, where each spectrum is averaged from three consecutive scans and have not been corrected for background fluorescence.
F19Cou IGF-II and F28Cou IGF-II. However, excitation at 280 nm of the sIGF-1R (donor) alone gave an intense emission at 332 nm (Fig. 4A: red solid line), which is due to the presence of endogenous Trp. Surprisingly, excitation at 280 nm of the sIGF-1R (donor) in the presence of native IGF-II resulted in fluorescence emission at 332 nm that was less intense than the fluorescence emission at 332 nm for the sIGF-1R alone (Fig. 4A: red solid line). This emission at 332 nm was also less intense than the sum of the individual emission spectra of native IGF-II and sIGF-1R (Fig. 4A: blue solid line). This large decrease in fluorescence at 332 nm indicates that the receptor (sIGF-1R) is extremely sensitive to ligand binding. The decrease is likely the result of extensive Trp quenching within the sIGF-1R, or perhaps a decrease in the quantum yield of the endogenous Trp within the sIGF-1R. This is an interesting result that suggests a change in the local environment of the IGF-1R Trp residues upon IGF-II binding, and supports the idea of a structural change in the receptor upon ligand binding.

An analysis of the fluorescence emission spectra for the F19Cou IGF-II analogue alone and in complex with the sIGF-1R is shown in Fig. 5. Excitation at 280 nm of the F19Cou IGF-II analogue alone (Fig. 5A: orange solid line) resulted in no fluorescence emission at 332 nm and a small intensity emission at 455 nm, and excitation of the sIGF-1R alone (donor) at 280 nm produced an intense emission peak at 332 nm (Fig. 5A: red solid line). Excitation at 280 nm of F19Cou IGF-II (acceptor) in the presence of the sIGF-1R (donor) (Fig. 5A: black solid line) resulted in fluorescence emissions at 332 nm and 455 nm. The fluorescence emission of the complex at 455 nm was increased compared to the fluorescence emission for the acceptor (F19Cou IGF-II) alone (Fig. 5A: orange solid line). Whereas the fluorescence emission of the complex at 332 nm was unchanged compared to the fluorescence emission spectrum for the donor (sIGF-1R) alone (Fig. 5A: red solid line), and was unchanged compared the sum of the individual emission spectra of the sIGF-1R and F19Cou IGF-II (Fig. 5A: blue solid line). This unaltered fluorescence emission at 332 nm suggests a lack of Trp quenching in the IGF-1R upon F19Cou IGF-II binding. Excitation at 320 nm of the F19Cou IGF-II (acceptor) alone (Fig. 5B: orange solid line) gave rise to fluorescence emission at 455 nm. The same fluorescence emission at 455 nm was also observed for the F19Cou IGF-II in complex with the sIGF-1R (acceptor & donor) (Fig. 5B: black solid line), after excitation at 320 nm. Importantly the fluorescence emission at 455 nm for F19Cou IGF-II in complex with the sIGF-1R (acceptor & donor) was identical in intensity to the emission for the F19Cou IGF-II alone (acceptor). These results demonstrate that fluorescence emission at 455 nm is enhanced upon F19Cou IGF-II binding to the receptor (sIGF-1R), and direct excitation (Ex 320 nm) of the coumarin residue is unaffected after ligand binding. Together these results confirm the F19Cou IGF-II coumarin fluorescence is sensitized.

Fig. 7 shows the acceptor emission data from the FRET interaction between F19Cou IGF-II and the sIGF-1R. Specifically, the extracted acceptor emission (Fig. 7: black dotted line) and the extracted FRET signal (Fig. 7: blue dotted line) are shown. Where the extracted acceptor emission (Fig. 7: black dotted line) was obtained by subtracting the donor (sIGF-1R) emission from the complex (sIGF-1R and F19Cou IGF-II) emission, and the FRET signal (Fig. 7: blue dotted line) was obtained by subtracting the donor (sIGF-1R) and acceptor (F19Cou IGF-II) spectra from the complex (sIGF-1R and F19Cou IGF-II) spectra. The extracted acceptor emission (Fig. 7: black dotted line) shows a fluorescence emission at 455 nm, which is consistent with coumarin emission. The emission was more intense than the fluorescence emission at 455 nm for the acceptor (F19Cou IGF-II) alone (Fig. 7: orange solid line). This increase in fluorescence emission at 455 nm is also visible in the extracted FRET signal shown in Fig. 7 (blue dotted line). Together these results suggest that the quantum yield of the Trp residues, within the IGF-1R, is enhanced by F19Cou IGF-II binding but is simultaneously and equally quenched by FRET. This results in the unaltered Trp emission seen in Fig. 5.

Fig. 6 depicts the FRET analysis of the F28Cou IGF-II alone and in complex with the sIGF-1R. Excitation at 280 nm of F28Cou IGF-II alone (acceptor) (Fig. 6A: solid green line) gave a low intensity fluorescence emission at 455 nm, and excitation at 280 nm of the F28Cou IGF-II in complex with sIGF-1R (donor & acceptor) (Fig. 6A: black solid line), gave fluorescence emissions at 332 nm and 455 nm. The fluorescence emission at 332 nm was less intense than the emission at 332 nm for the sIGF-1R alone (Fig. 6A: red solid line). While the fluorescence emission at 455 nm for the complex was more
intense than the emission at the same wavelength for the acceptor (F28Cou IGF-II) alone (Fig. 6A: green solid line).

The relative decrease in fluorescence at 332 nm between the complex and receptor alone is consistent with Trp quenching within the sIGF-1R upon F28Cou IGF-II binding, albeit to a lesser extent than with the native IGF-II (Fig. 4). While the increase in fluorescence emission at 455 nm for the complex compared to the acceptor (F28Cou IGF-II) alone, is consistent with a FRET interaction between the sIGF-1R and F28Cou IGF-II. Furthermore excitation at 320 nm gave fluorescence emission at 455 nm for both the F28Cou IGF-II in complex with the sIGF-1R (acceptor & donor) [Fig. 6B: black solid line] and F28Cou IGF-II alone (acceptor) [Fig. 6B: green solid line]. This emission was only slightly more intense for the F28Cou IGF-II in complex with the sIGF-1R than for the F28Cou IGF-II alone, and suggests direct excitation (Ex 320 nm) of the coumarin residue is relatively unaffected after ligand binding. These results are supported by the acceptor emission data shown in Fig. 8.

The extracted acceptor emission shown in Fig. 8 gave fluorescence emission at 455 nm, which is consistent with acceptor emission. This extracted emission was more intense than the fluorescence emission at 455 nm for the acceptor (F28Cou IGF-II) alone (Fig. 8: orange solid line). This emission is also shown in the extracted FRET signal (Fig. 8: blue dotted line). Together this data confirms the increase in the fluorescence emission at 455 nm is likely the result of a FRET interaction between the Trp residues of the IGF-1R and the coumarin of the F28Cou IGF-II analogue. A comparison of F19Cou IGF-II and F28Cou IGF-II acceptor emission spectra shown in Fig. 7 and 8 (blue dotted lines) shows the FRET signal for F19Cou IGF-II is stronger than the FRET signal for the F28Cou IGF-II analogue. This suggests that binding of F28Cou IGF-II to the sIGF-1R causes a decrease in the quantum yield of the receptor (sIGF-1R), leading to a decrease in fluorescence emission at 332 nm, which results in the reduced emission at 332 nm shown in Fig. 6.

A FRET interaction was expected for both site 1 (F28Cou IGF-II) and site 2 (F19Cou IGF-II) interactions as there are several naturally occurring Trp residues located adjacent to the putative IGF-II binding sites (including Trp residues 79, 127, 176, 244 for site 1 and 402, 404, 479, 519 601 and 618 for site 2) (see ESI†).19,27,28,43 Of these, the most likely donor candidates, identified from the X-ray crystallographic data of the insulin:IR interaction19,31 are Trp79, Trp519 and Trp544, as these residues are surface exposed and located approximately 18–25 Å from the proposed ligand binding site. As expected, an increase in fluorescence emission was not observed for the native IGF-II protein in the presence of the sIGF-1R, as it lacks a fluorescent probe (Fig. 4). However surprisingly binding of native IGF-II to the sIGF-1R causes a significant decrease in the Trp fluorescence of the sIGF-1R. The site 2, F19Cou IGF-II analogue (Fig. 5) displayed fluorescence emission that was sensitized, and Trp emission was unaltered. Finally, the F28Cou IGF-II analogue displayed Trp fluorescence which was lower in the presence of the sIGF-1R and the coumarin fluorescence of the F28Cou IGF-II analogue was sensitized. These results confirm that the coumarin probes of the F19Cou IGF-II and F28Cou IGF-II bind in close proximity (10–100 Å) to a Trp residue(s) within the IGF-1R and in turn Phe19 and Phe28 are appropriate sites within IGF-II for the incorporation of a fluorescent probe/FRET acceptor. The strong binding affinities and positive FRET results demonstrate these are good analogues for further FRET binding studies.

Conclusions

In conclusion, we report an efficient, modular synthesis of the native IGF-II protein and two fluorescent IGF-II analogues. A three fragment approach using a Val20–Cys21 ligation site, gave complete ligation in less than 47 h. The IGF-II proteins were isolated in comparable yields (0.1–1%) and importantly in higher purity compared to previously reported IGF-II syntheses (ca. 2%).44–46 The native IGF-II and two fluorescent IGF-II analogues bind with nanomolar affinity to the IGF-1R. Both the F19Cou IGF-II and F28Cou IGF-II proteins displayed a FRET interaction with the IGF-1R, with binding of the native IGF-II protein causing the largest quenching of IGF-1R fluorescence. These results demonstrate that the Trp residues within the sIGF-1R are extremely sensitive to ligand binding, and these coumarin probes bind in close proximity to Trp residues within the IGF-1R and as such are ideal analogues for investigating the interaction of IGF-II with its high affinity binding partners.
Acknowledgements

The authors would like to acknowledge Ms Carlie Delaine for preparation of the siGF-1R and Ms Clair Alvino for helpful discussions. The research was supported in part by the ARC Centre of Excellence in Nanoscale BioPhotonics (CNBP).

Notes and references

1 S. Kornfeld, Annu. Rev. Biochem., 1992, 61, 307–330.
2 E. Van Obberghen, Diabetologia, 1994, 37, S125–S134.
3 C. E. H. Stewart and P. Rotwein, Physiol. Rev., 1996, 76, 1005–1026.
4 A. Denley, L. J. Cosgrove, G. W. Booker, J. C. Wallace and B. E. Forbes, Cytokine Growth Factor Rev., 2005, 16, 421–439.
5 A. Belfiore, F. Frasca, G. Pandini, L. Sciacca and R. Vigneri, Endocr. Rev., 2009, 30, 586–623.
6 L. K. Harris and M. Westwood, Growth Factors, 2012, 30, 1–12.
7 H. Yu and T. Rohan, J. Natl. Cancer Inst., 2000, 92, 1472–1489.
8 M. N. Pollak, E. S. Schernhammer and S. E. Hankinson, Nat. Rev. Cancer, 2004, 4, 505–518.
9 A. A. Samani, S. Yakar, D. LeRoith and P. Brodt, Endocr. Rev., 2007, 28, 20–47.
10 F. Frasca, G. Pandini, L. Sciacca, V. Pezzino, S. Squatrito, A. Belfiore and R. Vigneri, Arch. Physiol. Biochem., 2008, 114, 23–37.
11 M. Pollak, Nat. Rev. Cancer, 2008, 8, 915–928.
12 E. J. Gallagher and D. LeRoith, Endocrinology, 2011, 152, 2546–2551.
13 A. Belfiore and R. Malaguarnera, Endocr. – Relat. Cancer, 2011, 18, R125–R147.
14 J. Gao, Y. S. Chang, B. Jallal and J. Viner, Cancer Res., 2012, 72, 3–12.
15 M. Pollak, Clin. Cancer Res., 2012, 18, 40–50.
16 J. Brown, E. Y. Jones and B. E. Forbes, in Vitamins & Hormones, ed. L. Gerald, Academic Press, 2009, vol. 80, pp. 699–719.
17 H. M. El-Shewy and L. M. Luttrel, in Vitamins & Hormones, ed. L. Gerald, Academic Press, 2009, vol. 80, pp. 667–697.
18 J. G. Menting, Y. Yang, S. J. Chan, N. B. Phillips, B. J. Smith, J. Whittaker, N. P. Wickramasinghe, L. J. Whittaker, V. Pandyarajan, Z.-L. Wan, S. P. Yadav, J. M. Carroll, N. Strokes, C. T. Roberts, F. Ismail-Beigi, W. Milewski, D. F. Steiner, V. S. Chauhan, C. W. Ward, M. A. Weiss and M. C. Lawrence, Proc. Natl. Acad. Sci. U. S. A., 2014, 111, E3395–E3404.
19 J. G. Menting, J. Whittaker, M. B. Margetts, L. J. Whittaker, G. K. W. Kong, B. J. Smith, C. J. Watson, L. Zakova, E. Kletvikova, J. Jiracek, S. J. Chan, D. F. Steiner, G. G. Dodson, A. M. Brzozowski, M. A. Weiss, C. W. Ward and M. C. Lawrence, Nature, 2013, 493, 241–245.
20 T. P. J. Garrett, N. M. McKern, M. Lou, M. J. Frenkel, J. D. Bentley, G. O. Lovrecz, T. C. Ellemann, L. J. Cosgrove and C. W. Ward, Nature, 1998, 394, 395–399.
21 T. E. Adams and V. C. E. T. P. J. G. C. W. Ward, Cell. Mol. Life Sci., 2000, 57, 1050–1093.
22 C. W. Ward, T. P. J. Garrett, N. M. McKern, M. Lou, L. J. Cosgrove, L. G. Sparrow, M. J. Frenkel, P. A. Hoyne, T. C. Ellemann, T. E. Adams, G. O. Lovrecz, L. J. Lawrence and P. A. Tulloch, Mol. Pathol., 2001, 54, 125–132.
23 P. De Meyts, Bioessays, 2004, 26, 1351–1362.
24 V. C. Epa and C. W. Ward, Protein Eng., Des. Sel., 2006, 19, 377–384.
25 M. Lou, T. P. J. Garrett, N. M. McKern, P. A. Hoyne, V. C. Epa, J. D. Bentley, G. O. Lovrecz, L. J. Cosgrove, M. J. Frenkel and C. W. Ward, Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 12429–12434.
26 N. M. McKern, M. C. Lawrence, V. A. Streltsov, M.-Z. Lou, T. E. Adams, G. O. Lovrecz, T. C. Ellemann, K. M. Richards, J. D. Bentley, P. A. Pilling, P. A. Hoyne, K. A. Cartridge, T. M. Pham, J. L. Lewis, S. E. Sankovich, V. Stoichyevska, E. Da Silva, C. P. Robinson, M. J. Frenkel, L. G. Sparrow, R. T. Fernley, V. C. Epa and C. W. Ward, Nature, 2006, 443, 218–221.
27 M. Keyhanfar, G. W. Booker, J. Whittaker, J. C. Wallace and B. E. Forbes, Biochem. J., 2007, 401, 269–277.
28 M. C. Lawrence, N. M. McKern and C. W. Ward, Curr. Opin. Struct. Biol., 2007, 17, 699–705.
29 C. Ward, M. Lawrence, V. Streltsov, T. Garrett, N. McKern, M. Z. Lou, G. Lovrecz and T. Adams, Acta Physiol., 2008, 192, 3–9.
30 C. W. Ward and M. C. Lawrence, Bioessays, 2009, 31, 422–434.
31 B. J. Smith, K. Huang, G. Kong, S. J. Chan, S. Nakagawa, J. G. Menting, S.-Q. Hu, J. Whittaker, D. F. Steiner, P. G. Katsoyannis, C. W. Ward, M. A. Weiss and M. C. Lawrence, Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 6771–6776.
32 J. Whittaker, L. J. Whittaker, C. T. Roberts, N. B. Phillips, F. Ismail-Beigi, M. C. Lawrence and M. A. Weiss, Proc. Natl. Acad. Sci. U. S. A., 2012, 109, 11166–11171.
33 C. L. Alvino, K. A. McNeil, S. C. Ong, C. Delaine, G. W. Booker, J. C. Wallace, J. Whittaker and B. E. Forbes, J. Biol. Chem., 2009, 284, 7656–7664.
34 R. M. Christie and C.-H. Lui, Dyes Pigm., 1999, 42, 85–93.
35 R. M. Christie and C.-H. Lui, Dyes Pigm., 2000, 47, 79–89.
36 B. Valeur and M. N. Berberan-Santos, Molecular Fluorescence: Principles and Applications, John Wiley & Sons, 2001.
37 J. R. Lakowicz, Principles of Fluorescence Spectroscopy, Springer, 3rd edn, 2006.
38 R. P. Haugland, The Molecular Probes Handbook: A Guide to Fluorescent Probes and Labeling Technologies, Life Technologies, 11th edn, 2010.
39 L. M. Wysocki and L. D. Lavis, Curr. Opin. Chem. Biol., 2011, 15, 752–759.
40 J. Wang, J. Xie and P. G. Schultz, J. Am. Chem. Soc., 2006, 128, 8738–8739.
41 M.-P. Brun, L. Bischoff and C. Garbay, Angew. Chem., Int. Ed., 2004, 43, 3432–3436.
42 L. Whittaker, C. Hao, W. Fu and J. Whittaker, Biochemistry, 2008, 47, 12900–12909.
43 J. Whittaker, A. V. Groth, D. C. Mynarcik, L. Pluzek, V. L. Gadsboll and L. J. Whittaker, J. Biol. Chem., 2001, 276, 43980–43986.
44 C. H. Li, D. Yamashiro, R. Glenn Hammonds Jr. and M. Westphal, Biochem. Biophys. Res. Commun., 1985, 127, 420–424.
45 D. Yamashiro and C. H. Li, Int. J. Pept. Protein Res., 1985, 26, 299–304.
46 Y. M. Oh, H. L. Muller, H. P. Zhang, N. Ling and R. G. Rosenfeld, in Current Directions in Insulin-Like Growth Factor Research, ed. D. LeRoith and M. K. Raizada, Plenum Press Div Plenum Publishing Corp, New York, 1993, vol. 343, pp. 41–54.
47 J. Cottam, D. Scanlon, J. Karas, A. Calabrese, T. Pukala, B. Forbes, J. Wallace and A. Abell, Int. J. Pept. Res. Ther., 2013, 19, 61–69.
48 Y. Sohma, B. L. Pentelute, J. Whittaker, Q.-X. Hua, L. J. Whittaker, M. A. Weiss and S. B. H. Kent, Angew. Chem., Int. Ed., 2008, 47, 1102–1106.
49 M. Schnölzer, P. Alewood, A. Jones, D. Alewood and S. B. H. Kent, Int. J. Pept. Protein Res., 1992, 40, 180–193.
50 E. C. B. Johnson and S. B. H. Kent, J. Am. Chem. Soc., 2006, 128, 6640–6646.
51 T. M. Hackeng, J. H. Griffin and P. E. Dawson, Proc. Natl. Acad. Sci. U. S. A., 1999, 96, 10068–10073.
52 R. C. d. L. Milton, S. C. F. Milton and P. A. Adams, J. Am. Chem. Soc., 1990, 112, 6039–6046.
53 M. Schnölzer, P. Alewood, A. Jones, D. Alewood and S. Kent, Int. J. Pept. Res. Ther., 2007, 13, 31–44.
54 P. Dawson, T. Muir, I. Clark-Lewis and S. Kent, Science, 1994, 266, 776–779.
55 M. Villain, J. Vizzavona and K. Rose, Chem. Biol., 2001, 8, 673–679.
56 C. Delaine, C. L. Alvino, K. A. McNeil, T. D. Mulhern, L. Gautuin, P. De Meets, E. Y. Jones, J. Brown, J. C. Wallace and B. E. Forbes, J. Biol. Chem., 2007, 282, 18886–18894.
57 C. L. Alvino, S. C. Ong, K. A. McNeil, C. Delaine, G. W. Booker, J. C. Wallace and B. E. Forbes, PLoS One, 2011, 6.
58 A. Denley, E. R. Bonython, G. W. Booker, L. J. Cosgrove, B. E. Forbes, C. W. Ward and J. C. Wallace, Mol. Endocrinol., 2004, 18, 2502–2512.
59 K. H. Surinya, B. E. Forbes, F. Occhiodoro, G. W. Booker, G. L. Francis, K. Siddle, J. C. Wallace and L. J. Cosgrove, J. Biol. Chem., 2008, 283, 5355–5363.